Cell Death Pathways: Molecular Mechanisms and Therapeutic Targets for Cancer

Overview

Journal MedComm (2020)

Specialty Health Services

Date 2024 Sep 6

PMID 39239068

Authors

Shaohui Wang

Sa Guo

Jing Guo

Qinyun Du

Cen Wu

Yeke Wu

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Cell death regulation is essential for tissue homeostasis and its dysregulation often underlies cancer development. Understanding the different pathways of cell death can provide novel therapeutic strategies for battling cancer. This review explores several key cell death mechanisms of apoptosis, necroptosis, autophagic cell death, ferroptosis, and pyroptosis. The research gap addressed involves a thorough analysis of how these cell death pathways can be precisely targeted for cancer therapy, considering tumor heterogeneity and adaptation. It delves into genetic and epigenetic factors and signaling cascades like the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways, which are critical for the regulation of cell death. Additionally, the interaction of the microenvironment with tumor cells, and particularly the influence of hypoxia, nutrient deprivation, and immune cellular interactions, are explored. Emphasizing therapeutic strategies, this review highlights emerging modulators and inducers such as B cell lymphoma 2 (BCL2) homology domain 3 (BH3) mimetics, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), chloroquine, and innovative approaches to induce ferroptosis and pyroptosis. This review provides insights into cancer therapy's future direction, focusing on multifaceted approaches to influence cell death pathways and circumvent drug resistance. This examination of evolving strategies underlines the considerable clinical potential and the continuous necessity for in-depth exploration within this scientific domain.

Citing Articles

Identification of ferroptosis-related genes in heart tissues of patients with hypertrophic cardiomyopathy.

Huang F, Li S, Zhang A, Zhao J, Zhang S, Liu D Medicine (Baltimore). 2025; 104(9):e41525.

PMID: 40020138 PMC: 11875581. DOI: 10.1097/MD.0000000000041525.

Ferroptosis in Pulmonary Disease and Lung Cancer: Molecular Mechanisms, Crosstalk Regulation, and Therapeutic Strategies.

Guo D, Cai S, Deng L, Xu W, Fu S, Lin Y MedComm (2020). 2025; 6(3):e70116.

PMID: 39991627 PMC: 11847630. DOI: 10.1002/mco2.70116.

N7-methylguanosine modification in cancers: from mechanisms to therapeutic potential.

Wu Q, Fu X, Liu G, He X, Li Y, Ou C J Hematol Oncol. 2025; 18(1):12.

PMID: 39881381 PMC: 11780989. DOI: 10.1186/s13045-025-01665-7.

mTOR Inhibitor Everolimus Modulates Tumor Growth in Small-Cell Carcinoma of the Ovary, Hypercalcemic Type and Augments the Drug Sensitivity of Cancer Cells to Cisplatin.

Zheng K, Gao Y, Xu J, Kang M, Chai R, Jin G Biomedicines. 2025; 13(1).

PMID: 39857585 PMC: 11759183. DOI: 10.3390/biomedicines13010001.

Age-Dependent Differences in Radiation-Induced DNA Damage Responses in Intestinal Stem Cells.

Zhou G, Shimura T, Yoneima T, Nagamachi A, Kanai A, Doi K Int J Mol Sci. 2024; 25(18).

PMID: 39337697 PMC: 11431935. DOI: 10.3390/ijms251810213.

References

Ashrafizadeh M, Paskeh M, Mirzaei S, Gholami M, Zarrabi A, Hashemi F . Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res. 2022; 41(1):105. PMC: 8939209. DOI: 10.1186/s13046-022-02293-6. View

Valentini E, Di Martile M, Brignone M, Di Caprio M, Manni I, Chiappa M . Bcl-2 family inhibitors sensitize human cancer models to therapy. Cell Death Dis. 2023; 14(7):441. PMC: 10352371. DOI: 10.1038/s41419-023-05963-1. View

Cao L, Mu W . Necrostatin-1 and necroptosis inhibition: Pathophysiology and therapeutic implications. Pharmacol Res. 2020; 163:105297. PMC: 7962892. DOI: 10.1016/j.phrs.2020.105297. View

Ozyerli-Goknar E, Bagci-Onder T . Epigenetic Deregulation of Apoptosis in Cancers. Cancers (Basel). 2021; 13(13). PMC: 8267644. DOI: 10.3390/cancers13133210. View

Wu H, Qian D, Bai X, Sun S . Targeted Pyroptosis Is a Potential Therapeutic Strategy for Cancer. J Oncol. 2022; 2022:2515525. PMC: 9715319. DOI: 10.1155/2022/2515525. View

Liu Z, Ma A, Mathe E, Merling M, Ma Q, Liu B . Network analyses in microbiome based on high-throughput multi-omics data. Brief Bioinform. 2020; 22(2):1639-1655. PMC: 7986608. DOI: 10.1093/bib/bbaa005. View

Di Pilato M, Kfuri-Rubens R, Pruessmann J, Ozga A, Messemaker M, Cadilha B . CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021; 184(17):4512-4530.e22. PMC: 8719451. DOI: 10.1016/j.cell.2021.07.015. View

Wibisana J, Okada M . Encoding and decoding NF-κB nuclear dynamics. Curr Opin Cell Biol. 2022; 77:102103. DOI: 10.1016/j.ceb.2022.102103. View

Debnath J, Gammoh N, Ryan K . Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023; 24(8):560-575. PMC: 9980873. DOI: 10.1038/s41580-023-00585-z. View

10.

Hsu S, Li C, Lin I, Syue W, Chen Y, Cheng K . Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. Theranostics. 2021; 11(18):8813-8835. PMC: 8419056. DOI: 10.7150/thno.62521. View

11.

Xu W, Huang Y . Regulation of Inflammatory Cell Death by Phosphorylation. Front Immunol. 2022; 13:851169. PMC: 8921259. DOI: 10.3389/fimmu.2022.851169. View

12.

Yang T, Wang G, Zhang M, Hu X, Li Q, Yun F . Triggering endogenous Z-RNA sensing for anti-tumor therapy through ZBP1-dependent necroptosis. Cell Rep. 2023; 42(11):113377. DOI: 10.1016/j.celrep.2023.113377. View

13.

Zhang T, Wang Y, Inuzuka H, Wei W . Necroptosis pathways in tumorigenesis. Semin Cancer Biol. 2022; 86(Pt 3):32-40. PMC: 11010659. DOI: 10.1016/j.semcancer.2022.07.007. View

14.

Pimentel J, Zhou J, Wu G . The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer. Cancers (Basel). 2023; 15(10). PMC: 10216286. DOI: 10.3390/cancers15102752. View

15.

Stalnecker C, Grover K, Edwards A, Coleman M, Yang R, DeLiberty J . Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Cancer Res. 2021; 82(4):586-598. PMC: 8886214. DOI: 10.1158/0008-5472.CAN-21-1443. View

16.

Menyhart O, Gyorffy B . Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J. 2021; 19:949-960. PMC: 7868685. DOI: 10.1016/j.csbj.2021.01.009. View

17.

DiNardo C, Lachowiez C, Takahashi K, Loghavi S, Xiao L, Kadia T . Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021; 39(25):2768-2778. PMC: 8407653. DOI: 10.1200/JCO.20.03736. View

18.

Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J . The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022; 12:985363. PMC: 9597512. DOI: 10.3389/fonc.2022.985363. View

19.

Shi F, Huang X, Hong Z, Lu N, Huang X, Liu L . Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. Cancer Lett. 2023; 562:216167. DOI: 10.1016/j.canlet.2023.216167. View

20.

Ketkar M, Dutt S . Epigenetic Regulation Towards Acquired Drug Resistance in Cancer. Subcell Biochem. 2022; 100:473-502. DOI: 10.1007/978-3-031-07634-3_14. View